NCT00501891View on ClinicalTrials.gov

Bevacizumab in Combination With Metronomic Temozolomide for Recurrent Malignant Glioma

PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

December 31, 2007

Study Completion Date

November 30, 2009

Conditions
Glioblastoma Multiforme
Interventions
DRUG

Bevacizumab

Bevacizumab administered intravenously 10mg/kg every other week.

DRUG

Metronomic Temozolomide

Temozolomide 50mg/m2 given orally on a daily basis.

Trial Locations (1)

27710

Duke University Medical Center (Brain Tumor Center), Durham

Sponsors

Lead Sponsor

Duke University
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

collaborator

Schering-Plough

INDUSTRY

lead

Duke University

OTHER